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Available online 9 December 2016Mammalian cardiac cells are important targets to the protozoan Trypanosoma cruzi. The inflammatory reaction in
the host aims at eliminating this parasite, can lead to cell destruction, fibrosis and hypoxia. Local hypoxia is well-
defined stimulus to the production of angiogenesis mediators. Assuming that different genetic T. cruzi popula-
tions induce distinct inflammation and disease patterns, the current study aims to investigate whether the pro-
duction of inflammatory and angiogenic mediators is a parasite strain-dependent condition. C57BL/6 mice were
infectedwith the Y and Colombian strains of T. cruzi and euthanized at the 12th and 32nd days, respectively. The
blood and heart tissue were processed in immune assays and/or qPCR (TNF, IL-17, IL-10, CCL2, CCL3, CCL5, CCR2,
CCR5 and angiogenic factors VEGF, Ang-1, Ang-2) and in histological assays. The T. cruzi increased the inflamma-
tory and angiogenicmediators in the infectedmicewhen theywere compared to non-infected animals. However,
the Colombian strain has led to higher (i) leukocyte infiltration, (ii) cardiac TNF and CCL5 production/expression,
(iii) cardiac tissue parasitism, and to higher (iv) ratio between heart/body weights. On the other hand, the Co-
lombian strain has caused lower production and expression VEGF, Ang-1 and Ang-2, when it was compared to
the Y strain of the parasite. The present study highlights that the T. cruzi-genetic population defines the pattern
of angiogenic/inflammatorymediators in the heart tissue, and that itmay contribute to themagnitude of the car-
diac pathogenesis. Besides, such assumption opens windows to the understanding of the angiogenic mediator's
role in association with the experimental T. cruzi infection.





Inflammation is a multifactorial process involving cellular activation
andmigration, inflammatorymediators' production, vascular responses
and local and/or systemic reactions. Angiogenesis emerges as an event
cross-linked to inflammation and it aims at keeping homeostasis and
repairing the tissue through the formation of new capillary networks
from a preexisting vasculature. These networks are tightly regulated
by the production and release of angiogenic factors (Medzhitov, 2008;
Folkman, 2006).e Ouro Preto, Laboratório de
orro do Cruzeiro, 35400-000The protozoan Trypanosoma cruzi triggers acute and chronic inflam-
matory processes in smooth, skeletal and cardiacmuscles and promotes
a progressive damage that causes local fibrosis prevalence and function-
ality deficit (Lannes-Vieira et al., 2009; Talvani and Teixeira, 2011;
Penitente et al., 2015). This parasite has a well-adapted mechanism
that favors its survival inmammalian host cells and drives an inflamma-
tory response in the host according to the T. cruzi high genetic variabil-
ity, which is evidenced through six distinct Discrete Typing
Units—DTU's expressed as T. cruzi I (TcI) to T. cruzi VI (TcVI). Each of
these units present a biological feature based on their geographic distri-
bution, and eco-epidemiological and clinical associations (Zingales et
al., 2012). The inflammatory response aims at eliminating the parasites
in the acute phase; whereas, in the chronic phase, such response is rath-
er kept under control in order to keep the parasites and the immune re-
sponse under control as a way to prevent excessive tissue damage
(Nagajyothi et al., 2012; Cardoso Reis-Cunha and Bartholomeu, 2015).
When these protective strategies fail, the pathophysiological
Table 1
Primer sequences according to the GenBank database.





















VEGF-A (Vascular Endothelial Growth factor A); ANG-1 (Angiopoietin 1); ANG-
2 (Angiopoietin 2); TNF (Tumor Necrosis Factor); IL-10 (Interleukin-10); CCL-
2/MCP-1 (Monocyte Chemoattractant Protein); CCL5/RANTES (Regulated
upon activation, normal T cell expressed and secreted); CCR2 (CCL2 receptor);
CCR5 (CCL5 receptor).
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pendence of the parasite DTUs.
It is likely that the immune response and the T. cruzimolecules trig-
ger the angiogenic factors since they are required to tissue repair
(Ferreira et al., 2005, Guedes-da-Silva et al., 2015). In turn, inflamma-
tion may lead to conditions favorable for angiogenesis, partly due to
the hypoxia that emerges after fibrosis generation and, partly, to the in-
flammatorymediators that are further amplified by pro-angiogenic fac-
tors released around the inflammatory site (Yamakawa et al., 2003, Van
Nieuwenhoven and Turner, 2013). Besides the conventional roles
played by cytokines and chemokines in the activation and recruitment
of leukocytes to the inflammatory foci, some other studies have
shown that these soluble mediators can directly or indirectly increase
the vascular growth by stimulating the production of the vascular endo-
thelial growth factor (VEGF) (Barcelos et al., 2009; Pickens et al., 2010;
Maloney and Gao, 2015). The VEGF is an essential factor responsible
for angiogenesis after its binding in the VEGF receptor, which is found
in many cells. It leads to the proliferation, migration and survival of
new endothelial cells (Leung et al., 1989; Bao et al., 2009; Zhang et al.,
2012; Wang et al., 2013). Furthermore, the angiopoietins can inhibit
the tumor necrosis factor (TNF)-stimulated leukocyte transmigration
and act as an important angiogenesis and inflammation regulator
(Gamble et al., 2000; Seok et al., 2013).
Since distinct genetic T. cruzi populations may cause different in-
flammation patterns in experimental models, the aim of the present
study is to show, for the first time, that the Y (DTU II) and Colombian
(DTU I) strains of T. cruzi perform different interactionswith angiogenic
and inflammatorymediators in the plasma and cardiac tissue of infected
C57BL/6 mice.
2. Materials and methods
2.1. Ethics statement
All procedures in the current studymeet the guidelines issued by the
Brazilian College of Animal Experimentation (COBEA); the researchwas
previously approved by the Ethics Committee on Animal Research of
UFOP (Protocol number 043/2010).
2.2. Experimental animals, parasites and infection
Ten week-old male C57BL/6 mice were bred and housed at the Ani-
mal Sciences Center at Universidade Federal de Ouro Preto—UFOP, Bra-
zil. The mice (n = 10) were infected with 100 blood trypomastigote
forms of T. cruzi using the following strains: (i) Y and (ii) Colombian.
The Y strain of T. cruzi, classified as DTU II, is characterized by a rapid
parasite multiplication with very high peaks between 9 and 10 days of
infection, presenting high virulence and mortality between 10 and
14 days of infection. The Colombian strain, classified as DTU I, presents
a very slow parasitic multiplication, reaching very high parasitemic
peaks between 20 and 30 days of infection, low virulence with nomor-
tality up to 50 days (Andrade andMagalhães, 1996; Zingales et al., 2012;
Zingales et al., 2009). Parasitemiawas daily determined according to the
method described by Brener (1962). The mice were euthanized after
the parasitemia peak, at the 12th and 32nd days of infection in the Y
and Colombian strains, respectively. Bloodwas collected for immunoas-
say; half heart (i) was fixed in 10% formalin for histological analysis, the
other half (ii) was used in molecular and immunoassay parameter
assessments.
2.3. Heart mass measurement
The heart from each animal was carefully excised after blood collec-
tion. The vessels and heart chambers were washed in phosphate buffer
solution. Thewet organwasweighed and the relative heart weight was
calculated using the heart weight in milligram/body weight in gram(mg/g). This mg/g value was used to determine the cardiac mass mea-
surement at the time of the euthanasia. In addition, both ventricles
were split in two fragments: the upper part was used in the homoge-
nate (immune and molecular assays); and the lower (apex) one, in
the histopathological analysis.
2.4. Immunoassay
The circulating levels of TNF, VEGF, IL-10, IL-17, the macrophage in-
flammatory protein alpha (MIP-alpha/CCL3) regulated upon activation,
normal T cell expressed and secreted normal T cells (CCL5/RANTES),
and the monocyte chemoattractant proteins (CCL2/MCP-1) were de-
tected in plasma. Blood from the orbital venous sinus (0.5 mL) was col-
lected during euthanasia and centrifuged (1500 g for 15 min at 4 °C).
The plasma was stored at −80 °C. In parallel, a 10 mg cardiac tissue
fragment collected from each animal was homogenized in cold
radioimmunoprecipitation assay (RIPA) buffer using a protease inhibi-
tor; the supernatant was stored at −80 °C. Next, these samples were
used to measure TNF, CCL2, CCL3, CCL5, IL-10, IL-17 and the angiogenic
factor VEGF (Peprotech, Ribeirão Preto, Brazil), according to the proto-
col recommended by the manufacturer. The samples were simulta-
neously measured in duplicates.
2.5. Morphometric and histopathological analysis
Cardiac tissue fragments were fixed in 10% buffered-formalin solu-
tion; then, dehydrated, cleared and embedded in paraffin in order to an-
alyze and quantify the inflammatory infiltration and the amastigote
nests. Blocks were cut in 4 mm-thick sections and stained in
hematoxyllin and eosin (HE). Twenty fields from each HE stained sec-
tion were randomly chosen at 40× magnification, thus totaling
74,931 μm2—the equivalent area of 50 fields of the analyzed myocardi-
um. Images were obtained in a Leica DM 5000 B micro chamber (Leica
Application Suite, UK, version 2.4.0 R1) and processed in the Leica
Quinn (V3) image analyzer software. The inflammatory process was
assessed through the number of cellular nuclei found in the infected
heart tissue and compared to the background of the cardiac cellular nu-
clei found in the non-infectedmice. Amastigote nestswere quantified in
the Image J 1.45s software, at the National Institute of Health, USA
(www.imagej.nih.gov/ij). The area occupied by parasites was assumed
Fig. 2. Concentrations of inflammatory mediators in the plasma. CCL2/MCP-1 (A), CCL5/RANTES (B) and CCL3/MIP-1 alpha (C) TNF (D), IL-17 (E) and IL-10 (F) were measured through
immunoassay (ELISA) in the plasma of C57BL/6 mice infected with the Colombian and Y strains of T. cruzi. Data are shown as the mean of 10 animals ± SEM and different letters
denote difference (p b 0.05).
Fig. 1. Parasitemia and relative heart weight of animals infected with different Trypanosoma cruzi strains. C57BL/6 mice were infected with Colombian and Y strains of T. cruzi (100
parasites/mouse) and (A) the parasitemia was assessed up to 12 days, in the Y strain, and up to 32 days, in the Colombian strain. (B) Animals were weighed before euthanasia and the
relative heart weight was expressed in (mg/g) 12 and 32 days after infection. The results are representative of 10 animals/group and expressed in median ± SEM. The p b 0.05
indicates difference between the uninfected animals and the Y strain-infected group.
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Fig. 3. Plasma production and cardiac expression of the vascular endothelial growth factor
(VEGF) in Trypanosoma cruzi infected animals. The VEGF was measured through ELISA in
(A) the plasma and in (B) the macerated cardiac tissue of C57BL/6 mice infected with the
Colombian and Y strains of T. cruzi. In parallel, (C) the cardiac VEGF was also measured
through quantitative-PCR. Data are shown as the mean ± SEM of 10 animals and the
expression of mRNA expression was normalized to the constitutive beta-actin gene.
Different letters denote difference in production and expression (p b 0.05).
59D. Shrestha et al. / Microvascular Research 110 (2017) 56–63to be the same area previously used to quantify the inflammatory
process.
2.6. Expression of the inflammatory and angiogenic mediators
We quantified the expression of inflammatory and angiogenic
genes. Thus, we extracted the total RNA from the cardiac tissue of the
animals with the SV Total RNA Isolation System Kit (Promega, USA) fol-
lowing the manufacturer's protocol. Subsequently, we made the com-
plementary DNA (cDNA) using the high-capacity cdna reverse
transcription kit (Applied Biosystems, USA). Then, for the angiogenic
(VEGF, Ang-1, Ang-2) and inflammatory (CCL2, CCL5, CCR2, CCR5, TNF
and IL-10) genes, a standard curve from serial dilutions of a known con-
centration of purified DNAwas achieved. This quantified DNA consisted
of the target PCRproduct prepared by conventional PCR from cDNApos-
itive for the corresponding target mRNA. Threefold measurement for
each standard dilution point over the whole standard curve range was
produced to generate a reliable standard curve. Then, real-time PCR
quantitative mRNA analyses were performed using an ABI Prism 7000
SDS unit (Applied Biosystems) through the Platinum® SYBR® Green
qPCR SuperMix UDG with ROX reagent (Invitrogen) for quantification
of amplicons. The standard PCR conditions were as follows: 50 °C
(2 min), 95 °C (10 min); 40 cycles of 94 °C (30 s), 58 °C (30 s), and
72 °C (1 min); followed by the standard denaturation curve. The se-
quences of the primers were designed using the Primer Express soft-
ware (Applied Biosystems) assuming the nucleotide sequences
available in the GenBank database (Table 1). In each reaction the Plati-
num® SYBR® Green qPCR SuperMix UDG with ROX reagent
(Invitrogen), 1 μg/μL of each specific primer, and cDNA diluted 20
times were used. In this study, all data were normalized to beta-actin
mRNA. Relative increase in CK and CKR were plotted in comparison to
the non-infected control group using 2 − Δ/Δ CT method.
2.7. Statistical analysis
Data are expressed as themean± standard error of themean (SEM)
and were analyzed using the Kolmogorov-Smirnov normality test and
One-Way analysis of variance. All analyses were performed using
PRISM 5.01 software (GraphPad, San Diego, CA, USA) and the level of
significance was accepted at p b 0.05.
3. Results
3.1. Parasitemia curve and the relative heart weight
The parasitemia curves are represented in Fig. 1A and show the bio-
logical feature of the Y and Colombian strains of T. cruzi used in the pres-
ent study. The pre-patent period ranged from 6 days, in the Y strain, to
10 days, in the Colombian strain of T. cruzi. Throughout the current
study, both strains have led to high parasite load in the infected
C57BL/6 mice. However, in the end of the acute phase, only mice infect-
ed with the Colombian strain of T. cruzi have presented increased heart/
body weight ratios. The animals infected with the Y strain kept heart/
body weight ratio similar to that of the non-infected animals (Fig. 2B).
3.2. The production and expression of plasma and heart inflammatory, reg-
ulatory and angiogenic mediators
The plasma cytokines (IL-10, IL-17 and TNF) and chemokines (CCL2,
CCL3, CCL5) production was quantified in order to be associated with
the inflammatory pattern of each T. cruzi strain, since the T. cruzi infec-
tion develops systemic inflammatory mediators and since these soluble
factors play a potential role in the release of angiogenic factors. All in-
fected animals have presented plasma elevation in the production of in-
flammatory/regulatory cytokines and chemokines when they were
compared to the uninfected mice (Fig. 2C). There was inverse relationbetween CCL2 and CCL5 production; the Y and Colombian strains have
induced more CCL2 (Fig. 2A) and CCL5 (Fig. 2B) in infected animals, re-
spectively. Interestingly, besides the pattern observed to the
chemokines, no differences were observed between both parasite
strains in TNF (Fig. 2D), IL-17 (Fig. 2E) and IL-10 (Fig. 2F) production
after the day of their respective parasitemia peaks.
In parallel, the vascular endothelial growth factor (VEGF), the main
representative among the angiogenic mediators, increased in the plas-
mawhen it was associatedwith both T. cruzi strains (Fig. 3A). However,
the DTU I, Colombian strain, was able to inhibit the VEGF production in
the heart tissue, which was measured in the tissue homogenate (Fig.
3B).
By following the plasma cytokines and chemokines production, the
cardiac expression of the CCL2 (Fig. 4A), CCL5 (Fig. 4B), TNF (Fig. 4C),
IL-10 (Fig. 4D), and the CCL2 and CCL5 receptors, respectively, CCR2
(Fig. 4E) and CCR5 (Fig. 4F) also increased in the presence of T. cruzi.
However, the Colombian strain was able to increase by 200 and by 6
times the expression of CCL5 (Fig. 4B) and TNF (Fig. 4C), respectively,
in the heart tissue of infected mice when it was compared to the Y
strain.
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through qPCR (Fig. 3C). The Colombian strain was, once more, capable
of inhibiting this angiogenic factor more intensely at molecular level
when it was compared to the Y strain of the parasite. Moreover, the ex-
pression of angiopoetin-1 (Ang-1) (Fig. 5A) and angiopoetin-2 (Ang-2)
(Fig. 5B), which are other angiogenic mediators, just decreased in ani-
mals infected with the Colombian strain of T. cruzi.
3.3. Inflammatory infiltration and parasitism in cardiac tissue
Although all animals have received the same load of parasites during
the infection, eachDTU has promoted specificities in the inflamed cardi-
ac tissue.With regard to the present study, the Colombian strainwas as-
sociated with higher leukocytes influx, followed by the Y strain (Fig.
6A). Fig. 6 (left side) shows a representative photomicrography of the
non-infected cardiac tissue and the presence of amastigote nests associ-
atedwith the T. cruzi (Colombian strain). These images are reinforced by
the quantification of the amastigote nest area (Fig. 6B). Tissue parasites
associated with the Y strain were not detected in the current study.
4. Discussion
There is noway to escape from the close relation between the genet-
ic variability of the T. cruzi, currently classified as DTU's, and the gener-
ation of the pathology and of cardiac diseases in humans and in
experimental animals (Zingales et al., 2012, 2009). However, the dis-
tinct genetic variability between mammalians is also another highlight
that must be considered in the T. cruzi pathogenic puzzle. The para-
site/host interaction dictates the immune balance or imbalance and
leads to serious disturbances in the affected organs (Penitente et al.,
2015; Guedes et al., 2010; Oliveira et al., 2012; Martins et al., 2013;
Bryan et al., 2016; de Oliveira et al., 2016). Some studies have proposed
that a panel of inflammatory mediators is related to the protection
against circulating or tissue infecting T. cruzi (Lannes-Vieira et al.,
2009; Talvani and Teixeira, 2011; Penitente et al., 2015; Guedes et al.,Fig. 4. Expression of cytokines, chemokines and chemokine receptors in the heart. CCL2/MC
measured through quantitative-PCR in the hearts of mice infected with the Colombian and Y s
different letters denote difference in expression (p b 0.05). The expression of mRNA expression2010; Gomes et al., 2003). Soluble mediators such as IFN-gamma, IL-
12, TNF and IL-17 were previously described to activate macrophages
and to circulate mononuclear cells in reactive oxygen species—ROS
(Guedes et al., 2010; Gupta et al., 2011; Magalhães et al., 2013; Costa
et al., 2006; Machado et al., 2000) in order to eliminate parasites.
Some other regulatory proteins are also released in order to control
the immune response intensity (e.g. IL-10, IL-4, IL-22) and, consequent-
ly, to contribute to pathogenic process decay of Chagas disease (Gomes
et al., 2003; Flórez et al., 2011; Poveda et al., 2014) in humans and in ex-
perimental animals infected with T. cruzi (Abrahamsohn, 1998; Hiyama
et al., 2001). Part of this pathogenic process is driven by the chemokines
(e.g. CCL2, CCL3, CCL5 and others) and was previously evidenced in
human and experimental T. cruzi infection (Talvani et al., 2000;
Teixeira et al., 2002; Talvani et al., 2004; Nogueira et al., 2012). These
small and soluble molecules are capable of recruiting leukocytes in the
bone marrow and of sending them to the blood, and/or of sending
them from the blood to the tissue, thus intensifying local inflammation
and parasite elimination.
This parasite-dependent inflammatory process is usually persistent
and contributes to tissue destruction, to toxic products release and to
local tissue hypoxia, thus culminating in a heart repair or remodeling
process (Rossi and Carobrez, 1985; Melo et al., 2011). This hypoxic en-
vironment is a required stimulus to the release of a new set of angiogen-
ic mediators such as VEGF, angiopoietin (Ang)-1 and Ang-2. These
mediators are involved in the angiogenesis process and in the modula-
tion of inflammatory activities (McCarter et al., 2006; Scholz et al.,
2015). The VEGF acts through tyrosine kinase receptors (VEGFRs)
expressed in myelomonocytic inflammatory cells, as well as in vascular
endothelial cells. The inhibition of the VEGF signaling has been assumed
to induce anti-inflammatory properties through the blockage of STAT-3
(Wang et al., 2013; Waldner et al., 2010). The angiopoietins are oligo-
meric-secreted glycoprotein ligands that bind to a Tie family of recep-
tors primarily expressed in the vascular endothelium. The expression
of the leukocyte adhesion molecules E-selectin, ICAM1, and VCAM1 is
usually suppressed through Ang-1; whereas, Ang-2 appears to be aP-1 (A), CCL5/RANTES (B), TNF (C), IL-10 (D), CCR2 (E) and CCR5 (F) expressions were
trains of T. cruzi. Data represent fold expression of the mean from 10 animals ± SEM and
was normalized to the constitutive beta-actin gene.
Fig. 5. Expression of Angiopoietin-1 and -2 in infected cardiac tissue. Angiopoietin-1 (A)
and Angiopoietin-2 (B) expressions were measured through quantitative-PCR in the
hearts of mice infected with the Colombian and Y strains of T. cruzi. Data represent the
fold expression of the mean from 10 animals ± SEM and the expression of mRNA
expression was normalized to the constitutive beta-actin gene. Different letters denote
difference in expression (p b 0.05).
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these immune regulatory mechanisms remains unclear, although
some studies point out PI3K and Akt as required in this pathway
(Brindle et al., 2006).Fig. 6. Cardiac inflammatory cells and amastigote nests. Cellular infiltration in the cardiac tissue
and the area of amastigote nests in (B). Data are shown as themean from 10 animals ± SEM. D
cardiac tissue or of tissue infected by T. cruzi (left) present 40× magnification. Black arrows =The magnitude of the regulatory, inflammatory or angiogenic medi-
ators appears to depend on the DTU's of the protozoan, which demands
care at the interpretation of the data on experimental and human infec-
tions. Indeed, according to the literature, the presence of the parasite or
of its antigen molecules (e.g. mucin-glycosylphosphatidylinositol) in
experimental animals is sufficient to trigger inflammatory protein/
lipid mediators (Talvani and Teixeira, 2011; Golgher and Gazzinelli,
2004; Rodrigues et al., 2012). However, it is now suggested that the
magnitude depends on the parasite strain.
The Colombian strain of T. cruzi is an inducer of high murine TNF
levels and, consequently, it is responsible for releasing high levels of dis-
tinct chemokines and of their receptors in the immune and cardiac cells
(Medeiros et al., 2009). The DTU I is an adaptive strain to infected heart
tissue (Oliveira et al., 2012) and it also presents biological features
concerning the resistance against available nitro derivative drugs anti-
T. cruzi such as benznidazole (Romanha et al., 2010; Gruendling et al.,
2015). This genetic parasite population led to reduction in the expres-
sion of the following angiogenic factors in the present study: VEGF,
Ang-1 and Ang-2; however, in the cardiac tissue only, not in the plasma
context. On the other hand, the Colombian strain promoted TNF, CCL5
and CCL3 increase in the plasma and/or in the cardiac tissue. The persis-
tence of the tissue amastigote forms, the increase of other inflammation
mediators (TNF, IL-17, chemokines) and the reduction of Ang-1 and
Ang-2may have reinforced themagnitude of the local inflammatory re-
sponse due to the presence of greater leukocyte infiltration.
On the other hand, the Y strain of T. cruzi has also induced TNF and
other inflammatory mediators, but it was less intense than in the Co-
lombian strain. This genetic population of the parasite was homoge-
neous throughout different organs, including the heart (Oliveira et al.,
2012). It is partially resistant against derivative drugs anti-T. cruzi
(Romanha et al., 2010; Gruendling et al., 2015). The Y strain of T. cruzi
in the current study has induced higher expression of cardiac VEGF,
Ang-1 and Ang-2 in comparison to the lower production and/or expres-
sion of TNF, CCL5, amastigotes and leukocytes infiltration, which were
observed in the Colombian strain. The chemokine receptorswere herein
higher expressed during the expression of both T. cruzi strains, aswell asof C57BL/6mice infectedwith the Colombian and Y strains of T. cruziwas quantified in (A),
ifferent letters denote difference in expression (p b 0.05). Illustrations from the uninfected
amastigote nests.
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compared to animals who had no contact with the protozoan.
It is plausible that both polar populations of T. cruzi have led to in-
creased, but distinct, patterns of inflammatory and angiogenic media-
tors in the experimental infection model. The persistence of parasites
triggering inflammation in the cardiac tissuemay cause local oxygen re-
duction, hypoxia, and it may trigger favorable conditions to VEGF secre-
tion (Liu et al., 1995; Krock et al., 2011). The local inflammatory process
and the new tissue repair environment activate the platelet used as the
first vascular component to release VEGF after thrombin stimulation
(Möhle et al., 1995). The monocytes expressing the Flt-1 receptor can
be attracted by this VEGF, which, in part, is activated by TNF. In turn,
the TNF may induce more VEGF expression through the local cells
(Clauss et al., 2001; Lu et al., 2012). As for the present study, VEGF,
Ang-1 and Ang-2 have presented low expression in the heart tissue of
animals infected with the Colombian strain and presented higher
amastigote nests. Accordingly, the proinflammatory activity of VEGF
seems to have been balanced by the low activity of Ang-1 and Ang-2
during the infection with both genetic populations of T. cruzi.
5. Conclusion
The present study has demonstrated that DTU I (Y strain) and DTU II
(Colombian strain) T. cruzi parasites promote the release and the ex-
pression of different levels of angiogenic and inflammatory mediators
in the acute phase of the experimental infection. In this particular
case, the angiogenic mediators may work side by side with chemokines
and inflammatory cytokines in order to switch “on/off” the cardiac tis-
sue pathogenesis development, depending on the features dictated by
each DTU of the parasite.
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